Symbiotec Pharmalab: The financial results for the period ended September 30, 2026
Symbiotec Pharmalab (SYMBIOTEC) filed a disclosure titled "The financial results for the period ended September 30, 2026". The company is valued at about ₹8,170 crore.
What happened
Symbiotec Pharmalab (SYMBIOTEC) filed a disclosure with the exchanges on 5 November 2026 at 08:07 PM titled "The financial results for the period ended September 30, 2026".
Company snapshot
Symbiotec Pharmalab is a small-cap company, with a market value of about ₹8,170 crore.
The stock last traded at ₹1,271.5, against a 52-week range of ₹934.2–₹1,309.9 (2.9% below the high).
Before this filing the shares had moved +5.4% over the month. Average daily turnover over the last 20 sessions was about ₹82.18 crore.
Promoters held 33.28% at the end of Q2 FY27. Foreign institutions owned 21.08% and domestic institutions 27.52%.
What history shows
This is not the company's first results disclosure: BCEIE has 2 earlier filings of this kind on record since May 2026.
After those filings, the stock fell 8.1% on average the next trading day and was down 1.0% on average after five days (2 filings with price data).
Market-wide, 10,840 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 21 Sept 2026 | A press release dated September 21, 2026, titled "Investor Release… | −8.1% | −1.0% |
| 21 Sept 2026 | , the financial results for the period ended Jun 30, 2026. | −8.1% | −1.0% |
Market reaction so far
Since the filing, the stock has risen 3.1%, from ₹1,233.2 before the disclosure to ₹1,271.5 (last close).
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 5 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.